A mathematical model for the rational design of chimeric ligands in selective drug therapies

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 2, 2013, Pages

  Doldan Martelli V ^a   Guantes, R ^a   Miguez D G ^a  

^a INSTITUTO NICOLÁS CABRERA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERFERON;

ARTICLE; CELL TYPE; DRUG THERAPY; EMPIRICAL RESEARCH; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION;

EID: 84881147996     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.2     Document Type: Article

References (35)

1. Kawakami, K., Aggarwal, B.B. & Puri, R.K. Cytotoxins and Immunotoxins for Cancer Therapy: Clinical Applications 1st edn., (CRC Press, Taylor & Francis, Boca Raton, FL, 2004).
2. Turturro, F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoidderived disorders. Expert Rev. Anticancer Ther. 7, 11-17 (2007). (Pubitemid 46157644)
3. Kreitman, R.J. et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18, 1622-1636 (2000). (Pubitemid 30220540)
4. Kreitman, R.J. et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 23, 6719-6729 (2005). (Pubitemid 46190267)
5. Kioi, M., Husain, S.R., Croteau, D., Kunwar, S. & Puri, R.K. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol. Cancer Res. Treat. 5, 239-250 (2006). (Pubitemid 43946257)
6. Ruoslahti, E., Bhatia, S.N. & Sailor, M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188, 759-768 (2010).
7. Bremer, E. et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. 280, 10025-10033 (2005). (Pubitemid 40395853)
8. Bremer, E. et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res. 65, 3380-3388 (2005). (Pubitemid 40524623)
9. Stieglmaier, J. et al. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol. Immunother. 57, 233-246 (2008). (Pubitemid 350159925)
10. Bremer, E., ten Cate, B., Samplonius, D.F., de Leij, L.F. & Helfrich, W. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 107, 2863-2870 (2006).
11. Bremer, E. et al. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res. 68, 597-604 (2008). (Pubitemid 351380089)
12. Xuan, C., Steward, K.K., Timmerman, J.M. & Morrison, S.L. Targeted delivery of interferonalpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115, 2864-2871 (2010).
13. Zhang, B., Gao, B., Dong, S., Zhang, Y. & Wu, Y. Anti-tumor efficacy and pre-clinical immunogenicity of IFNa2a-NGR. Regul. Toxicol. Pharmacol. 60, 73-78 (2011).
14. Cironi, P., Swinburne, I.A. & Silver, P.A. Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. J. Biol. Chem. 283, 8469-8476 (2008).
15. Hannigan, G. & Williams, B.R. Transcriptional regulation of interferon-responsive genes is closely linked to interferon receptor occupancy. EMBO J. 5, 1607-1613 (1986).
16. Spencer, S.L. & Sorger, P.K. Measuring and modeling apoptosis in single cells. Cell 144, 926-939 (2011).
17. O'Brien, E.P., Morrison, G., Brooks, B.R. & Thirumalai, D. How accurate are polymer models in the analysis of Förster resonance energy transfer experiments on proteins? J. Chem. Phys. 130, 124903 (2009).
18. Yarden, Y. & Schlessinger, J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry 26, 1434-1442 (1987). (Pubitemid 17045874)
19. Uze, G., Lutfalla, G. & Mogensen, K.E. In Guidebook to Cytokines and Their Receptors (ed. Nicola, N.A.), 115-118 (Oxford UniversityPress, Oxford; New York; Tokyo, 1994).
20. Caraglia, M. et al. Interferon-alpha induces apoptosis in human KB cells through a stressdependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ. 6, 773-780 (1999). (Pubitemid 29425388)
21. Lauffenburger, D.A. & Linderman, J. Receptors: Models for Binding, Trafficking, and Signaling 130-180 (Oxford University Press, Huntington Beach, CA, 1996).
22. Adam, G. & Delbruck, M. Structural Chemistry in Molecular Biology 198-215 (Freeman, San Francisco, CA, 1968).
23. Zhao, L., Kroenke, C.D., Song, J., Piwnica-Worms, D., Ackerman, J.J. & Neil, J.J. Intracellular water-specific MR of microbead-adherent cells: the HeLa cell intracellular water exchange lifetime. NMR Biomed. 21, 159-164 (2008). (Pubitemid 351351008)
24. Shankaran, H., Resat, H. & Wiley, H.S. Cell surface receptors for signal transduction and ligand transport: a design principles study. PLoS Comput. Biol. 3, e101 (2007).
25. Darnell, J.E. Jr, Kerr, I.M. & Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421 (1994). (Pubitemid 24217131)
26. Pestka, S., Langer, J.A., Zoon, K.C. & Samuel, C.E. Interferons and their actions. Annu. Rev. Biochem. 56, 727-777 (1987). (Pubitemid 17105465)
27. Arteaga, C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19, 32S-40S (2001). (Pubitemid 32880077)
28. Dunne, S.L., Bajzer, Z. & Vuk-Pavlovic, S. Kinetics of receptor-mediated uptake and processing of interferon-alpha 2a and tumor necrosis factor-alpha by human tumor cells. Growth Factors 2, 167-177 (1990). (Pubitemid 20057754)
29. Piehler, J., Roisman, L.C. & Schreiber, G. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J. Biol. Chem. 275, 40425-40433 (2000). (Pubitemid 32064677)
30. Hendriks, B.S., Orr, G., Wells, A., Wiley, H.S. & Lauffenburger, D.A. Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells. J. Biol. Chem. 280, 6157-6169 (2005). (Pubitemid 40280101)
31. Resat, H., Ewald, J.A., Dixon, D.A. & Wiley, H.S. An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophys. J. 85, 730-743 (2003). (Pubitemid 36909642)
32. Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 (2002). (Pubitemid 35291060)
33. Garrett, T.P. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110, 763-773 (2002). (Pubitemid 35283965)
34. Xiao, Z., Zhang, W., Yang, Y., Xu, L. & Fang, X. Single-molecule diffusion study of activated EGFR implicates its endocytic pathway. Biochem. Biophys. Res. Commun. 369, 730-734 (2008).
35. Roisman, L.C., Piehler, J., Trosset, J.Y., Scheraga, H.A. & Schreiber, G. Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking. Proc. Natl. Acad. Sci. U.S.A. 98, 13231-13236 (2001). (Pubitemid 33051345)